Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £13.70m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

Phantom Carried Interest Scheme

19 May 2026 07:00

RNS Number : 8024E
EMV Capital PLC
19 May 2026
 

Strictly embargoed for: 07.00 a.m. on 19 May 2026

 

EMV Capital plc

(EMV Capital or EMVC or the Company or the Group)

Adoption of Phantom Carried Interest Scheme and Related Party Transaction

EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, today announces the adoption of its phantom carried interest scheme (PCI Scheme) in favour of its Executive Directors and certain PDMRs.

Background to and rationale for the adoption of the PCI Scheme

The Company has previously announced its desire to implement the PCI Scheme as a means of providing long-term incentives to key employees in line with typical venture capital (and private equity) industry standards.

The purpose of the PCI Scheme is to provide the Company with additional means of:

· providing long-term incentives to key employees to augment remuneration packages that may be limited by the current-day cash resources of the Company, bringing them in line with competitors and rewarding high performance;

· aligning participants with the long-term objectives of the Company and the interests of its shareholders;

· consolidating, developing and promoting the Group's collegiate culture and to working as a team to actively drive the value of its portfolio companies through to profitable exits; and

· retaining and recruiting a strong team, providing infrastructure and opportunity to grow and progress long-term careers within the Group.

A summary of the principal terms of the PCI Scheme follows.

Determination of Phantom Carried Interest under the PCI Scheme

The PCI Scheme creates a cash bonus pool from a proportion of investment returns (Investment Returns) paid to the Group upon the exit of each of its interests in portfolio companies. The proportion of Investment Returns to be added to that pool (Phantom Carried Interest or PCI) is determined each year by reference to Investment Returns received in the previous financial year. PCI is determined in the following two ways:

· for each of the Group's direct investments in portfolio companies, by subtracting from the Investment Return: (i) the total investment amount or for a limited number of portfolio companies, their fair value in August 2020; and (ii) a 'hurdle' rate (expected to be 8 per cent.). Of that resulting amount, 20 per cent. shall constitute Phantom Carried Interest and a 'catch-up' shall be applied to ensure an overall 80:20 division between the Company's and Participants' respective interests in profits arising from each exit. Where there are any realised losses in respect of direct interests in portfolio companies, 20 per cent. of those losses would be subtracted from the PCI pool. Similarly, 20 per cent. of material unrealised losses would be subtracted from the PCI pool (and added back should such unrealised losses cease to be material); and

· for each of the Group's indirect interests in portfolio companies (being interests arising from the Group's rights to contractual payments of performance fees/carried interest due from third party investors in portfolio companies upon profitable exits, which interests are not investments made from the Group's balance sheet), PCI is determined as 40 per cent. of Investment Returns after subtracting any amounts due to third parties in connection with their services for capital introductions to portfolio companies.

Participants in the PCI Scheme

The PCI Scheme is intended for the Executive Directors and certain members of the Senior Leadership Team (SLT), with participants (Participants) being admitted by the Remuneration Committee.

The initial Participants comprise the Executive Directors, Ilian Iliev and Ed Hooper, and PDMRs (and members of the SLT), Anesh Patel, Nick Salisbury and Harry Miller.

Awards under the PCI Scheme

Participants are awarded with points (Points) with each Point having an equal right (amongst the other qualifying Points) to a share of Phantom Carried Interest.

In total, 233 Points have been initially awarded as shown in the table below.

Participant name

Role

Points

Ilian Iliev

CEO

100

Ed Hooper

Executive Director

67

Nick Salisbury

Head of Capital Raising and Co-Investment

27

Harry Miller

Head of Research

27

Anesh Patel

Group CFO

12

Total

 

233

The Remuneration Committee may:

· award new Points to new Participants, setting vesting dates and/or conditions in respect thereof; and/or making Points specific to only some portfolio companies; and

· adjust a Participant's Points and/or award bonus Points, thereby adjusting the potential payments to Participants but not affecting the total payments to all Participants.

No Points may be awarded after the tenth anniversary of the date of adoption of the PCI Scheme.

Payments under the PCI Scheme

PCI shall be divided between Participants (who have passed any vesting or other conditions) by reference to their respective Points. To assist with retention, payments to each Participant are to be divided into three equal tranches over three years.

The Remuneration Committee may:

· defer the payment of initial instalments in circumstances where cash is required for going concern purposes; and

· settle up to 50 per cent. of payments to any Participant in the form of ordinary shares in the capital of the Company.

Acceleration of payments under the PCI Scheme shall occur on the change of control of the Company and certain liquidation and insolvency scenarios.

Customary 'malus and clawback' provisions apply to the PCI Scheme.

Departing Participants

The PCI Scheme contains customary provisions dealing with the departure of Participants, categorised as 'good leavers', 'intermediate leavers' and 'bad leavers' and is designed to reward long term service, with good leavers maintaining a crystalised right to future PCI following their departure, intermediate leavers receiving a discounted amount of future PCI and bad leavers ceasing to have any further rights to PCI.

Related party transaction

The Directors, excluding Ilian Iliev and Ed Hooper (by reason of their participation in the PCI Scheme), consider that the above-mentioned awards to Ilian Iliev and Ed Hooper under the PCI Scheme are fair and reasonable in so far as the Company's shareholders are concerned.

EMV Capital Non-Executive Chair, Charles Spicer, commented:

"Our new PCI Scheme is designed to align our senior leadership team directly with shareholders. Rewards are only generated from successful exits, after capital and performance hurdles are met, meaning the team benefits only when shareholders do. It reflects venture capital practice, supports long-term value creation at EMV Capital, as well as enabling us to attract and retain top talent from the industry."

 

The person responsible for arranging the release of this announcement on behalf of the Company is Ed Hooper, Executive Director and General Counsel of the Company.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

-ends-

 

For more information, please contact:

 

EMV Capital plc

via Rosewood

Ilian Iliev, CEO

 

 

Panmure Liberum Limited (NOMAD and Broker)

+44 (0)20 7886 2500

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

 

Rupert Dearden (Corporate Broking)

 

 

 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce

 

About EMV Capital plc (EMVC)

EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

· capital-efficient investments through the Group balance sheet;

· fund management of the Evergreen EIS and Martlet Capital Funds; and

· syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURBIGDUBXBDGLI
12
Date   Source Headline
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
2nd Oct 20244:38 pmRNSPDS: 36-Month Overall Survival Rate announcement
30th Sep 20247:00 amRNSInterim Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.